Summary of Suzhou Ribo Life Science (6938.HK) Conference Call Company Overview - **Company**: Suzhou Ribo Life Science - **Ticker**: 6938.HK - **Industry**: siRNA Drug Development Key Points Industry and Market Potential - The global oligonucleotide drug market is projected to grow from **US$5.7 billion in 2024** to **US$54.9 billion by 2034**, with a CAGR of **29.4% from 2024 to 2029** and **21.6% from 2029 to 2034** [28][29] - siRNA drugs are expected to capture a greater market share, outpacing other oligonucleotide modalities [28] Company Strengths - Ribo is a pioneer in siRNA technology with a robust pipeline of **seven in-house discovered drug assets** in clinical trials targeting cardiovascular, metabolic, renal, and liver diseases [12][3] - Proprietary delivery technologies, including **RiboGalSTARTM**, enhance targeting specificity and safety, positioning Ribo as a leader in siRNA therapeutics [25][26] - Collaborations with major pharmaceutical companies, including **Boehringer Ingelheim** and **Madrigal**, with total deal value exceeding **US$6.0 billion** [4][26] Key Products - **RBD4059**: A potential first-in-class FXI-targeting siRNA drug for thrombotic diseases, with estimated peak sales potential of **US$6.8 billion** [2][15] - **RBD5044**: A potential best-in-class APOC3-targeting siRNA for hypertriglyceridemia, showing competitive triglyceride-lowering efficacy [21] - **RBD1016**: A promising siRNA candidate for chronic hepatitis B (CHB) and coronary heart disease (CHD), with favorable safety and efficacy profiles [22][23] Financial Overview - **2023 Net Profit**: -RMB 428 million - **2024 Net Profit**: -RMB 270 million, with an expected EPS growth of **36.9%** [5][9] - **Target Price**: HK$102, representing an expected share price return of **73.5%** [6][11] Clinical Development and Efficacy - RBD4059 has shown a **dose-dependent reduction** in FXI activity, with maximum percentage changes from baseline of **67.5% to 91.6%** across different dosing cohorts [37] - The phase 2a trial for RBD4059 is expected to complete by the end of **2025** [35] Risks and Challenges - Key risks include potential R&D failures, slower-than-expected product launches, competition, and historical lack of profitability [4][11] Conclusion - Suzhou Ribo Life Science is positioned as a leader in the siRNA therapeutic space with significant growth potential driven by innovative products and strategic collaborations. The company faces challenges typical of biotech firms, including the need for successful clinical outcomes and market acceptance.

Investment Rating - The report assigns a "Buy" rating for RiboBio-B (06938) as a first-time coverage [1][7]. Core Insights - RiboBio focuses on the development and industrialization of small nucleic acid drugs, being one of the pioneers in this field. The company has established a fully integrated research and development platform for small nucleic acid drugs, covering various chronic diseases such as cardiovascular, metabolic, kidney, and liver diseases [5][17]. - The small nucleic acid drug industry is entering a period of explosive growth, with a projected compound annual growth rate (CAGR) of 29.4% from 2024 to 2029, driven by advancements in delivery technology and the expansion of indications from rare diseases to chronic diseases [27][28]. - RiboBio's differentiated pipeline includes RBD4059, which targets FXI for thrombotic diseases, RBD5044 for dyslipidemia, and RBD1016 for hepatitis B functional cure, showcasing the company's potential to meet unmet clinical needs [32][46]. Financial Data and Profit Forecast - The company is expected to generate revenues of RMB 143 million in 2024, with a projected growth to RMB 350 million in 2026 and 2027. The net profit attributable to ordinary shareholders is forecasted to be -RMB 270 million in 2024, improving to -RMB 133 million in 2026 [6][8]. - The target price for RiboBio is set at RMB 76.24, equivalent to HKD 86.08, indicating a potential upside of 46% from the market capitalization as of March 4, 2026 [7][8]. Pipeline and Market Opportunities - RiboBio has a robust pipeline with over 20 preclinical drugs and 7 clinical drugs, including 4 in Phase II trials. The core pipeline targets chronic diseases, addressing significant unmet clinical needs [30][31]. - RBD4059 is positioned as the world's first clinical-stage siRNA drug for thrombotic diseases, with a significant market potential as the global anti-thrombotic market is expected to reach USD 59.3 billion by 2024 [32][33]. - RBD5044 aims to address the unmet needs in the dyslipidemia market, which is projected to grow from USD 24 billion in 2019 to USD 35.3 billion by 2029 [46][49]. Key Assumptions and Catalysts - The revenue for 2025-2027 is primarily expected to come from business development (BD) licensing income, with significant milestone payments anticipated from collaborations with partners like Boehringer Ingelheim and Qilu Pharmaceutical [8][9]. - Key clinical data releases for RBD4059, RBD5044, and RBD1016, as well as new licensing agreements with overseas companies, are expected to act as catalysts for stock price performance [10].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market this week, with a 0.68% decline in the biotechnology sector compared to a 0.03% increase in the overall A-share market [1] - The report highlights the successful listing of Rebio Biotech on the Hong Kong Stock Exchange, focusing on the small RNA industry and its potential [2] - Rebio Biotech has established a proprietary delivery platform, RiboGalSTAR, and has entered into commercialization partnerships valued at over $2 billion [2] - The core asset RBD4059, targeting FXI, is currently in clinical phase 2a studies in Sweden, showing promise in treating thrombotic diseases [2][21] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the Shanghai Composite Index decreased by 0.57%. The biotechnology sector saw a decline of 0.68% [1][26] - Within the biotechnology sector, chemical pharmaceuticals fell by 2.40%, while medical services rose by 3.29% [1][26] Company Overview - Rebio Biotech focuses on small RNA drug development, with seven products in clinical research, four of which are in phase 2 trials [2][9] - The company has a strong management team with extensive experience in drug development and production [16][18] Financial Projections - The report provides earnings forecasts for key companies, with Rebio Biotech's core asset RBD4059 showing significant potential in the thrombotic disease market [3][21] - The report recommends investment opportunities in the CXO sector and highlights the clinical progress of innovative drugs overseas [2][36] Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 38.70x, compared to 22.18x for the overall A-share market [31] - Specific sub-sectors show varying P/E ratios, with chemical pharmaceuticals at 47.60x and medical services at 36.15x [31]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market, with a TTM P/E ratio of 38.70x, which is at the 84.85th percentile of the past five years [1][31] - The report highlights the recent IPO of RiboBio, a leading company in the small RNA drug development sector, which has established a proprietary delivery platform, RiboGalSTAR, focusing on cardiovascular, metabolic, renal, and liver diseases [2][9] - RiboBio has seven products in clinical research, with four advancing to Phase II trials, demonstrating the effectiveness and safety of its delivery system [2][17] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the biopharmaceutical sector declined by 0.68%, with chemical pharmaceuticals dropping by 2.40% [1][26] - The report notes significant individual stock movements, with some companies experiencing substantial gains and others facing steep declines [26][30] Company Focus: RiboBio - RiboBio has formed strategic partnerships with Boehringer Ingelheim and Qilu Pharmaceutical, with a total transaction value exceeding $2 billion, validating the platform's value [2][17] - The core asset, RBD4059, is in Phase IIa trials in Sweden for treating thrombotic diseases, showing promising results in reducing thrombus formation without increasing bleeding risk [2][21] - RBD4059's clinical data indicates a significant reduction in FXI activity, with a maximum percentage change of 91.6% at the highest dosage [22] Investment Recommendations - The report suggests focusing on investment opportunities in the CXO sector and the clinical progress of innovative drugs overseas [2] - Specific companies recommended for investment include Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [3][36]

Core Viewpoint - Ribo Life Science, a leader in the small nucleic acid pharmaceutical field, successfully listed on the Hong Kong Stock Exchange, achieving a market capitalization exceeding HKD 13 billion, representing over 30 times growth compared to its valuation after the A-round investment by Panlin Capital [1][5]. Company Overview - Ribo Life Science was founded in 2007 and is a pioneer in small nucleic acid (siRNA) drug research and development in China, establishing a comprehensive platform for small nucleic acid drug development [7]. - The company focuses on iterative research and development of small nucleic acid chemical modifications and drug delivery technologies, supporting all stages from early research to commercialization [7]. Product Pipeline - Ribo Life Science has developed a robust product pipeline, including: - RBD4059, a siRNA drug targeting FXI for treating thrombotic diseases, which has completed all subject enrollments in Phase IIa clinical trials [8]. - RBD5044, targeting APOC3 for treating hypertriglyceridemia, has received EU approval for Phase II clinical trials [8]. - RBD7022, targeting PCSK9 for treating hypercholesterolemia, has completed Phase I trials in China and is advancing to Phase II trials [8]. - RBD1016, targeting HBV for chronic hepatitis B treatment, is in Phase II trials and has received orphan drug designation from the EMA [10]. Globalization and Commercialization Strategy - Ribo Life Science integrates local R&D advantages with international expertise, establishing a world-class small nucleic acid drug development system [12]. - The company has multiple R&D centers in Suzhou, Beijing, and Europe, and successfully completed a USD 33 million equity financing for its overseas R&D center in Sweden [12]. Strategic Partnerships - In December 2023, Ribo Life Science entered into a licensing and collaboration agreement with Qilu Pharmaceutical for the development and commercialization of RBD7022 in Greater China, receiving over RMB 700 million in upfront and milestone payments [13]. - The company also signed a collaboration agreement with Boehringer Ingelheim to develop innovative therapies for NASH/MASH using its proprietary RiboGalSTAR™ technology, with a total transaction value exceeding USD 2 billion [13]. Investment Journey - Panlin Capital has been a key investor in Ribo Life Science since its A-round financing in 2015, providing crucial support during challenging times in the small nucleic acid industry [5][14]. - The investment journey includes six rounds of funding, demonstrating a commitment to supporting the company's growth and innovation in the biopharmaceutical sector [14][19].

Core Viewpoint - Suzhou Rebio Technology Co., Ltd. (Rebio) has successfully listed on the Hong Kong Stock Exchange, with its share price closing at HKD 82.10, reflecting a 41.62% increase from the issue price of HKD 57.97 [1][2]. Group 1: Company Overview - Rebio is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1]. - The total number of shares issued in this offering was 31,610,400 H-shares, with 2,748,800 shares allocated for public offering in Hong Kong and 28,861,600 shares for international placement [2]. Group 2: Financial Details - The total proceeds from the offering amounted to HKD 1,832.45 million, with net proceeds of HKD 1,701.80 million after deducting estimated listing expenses of HKD 130.65 million [2][3]. - The funds raised will be allocated to the research and development of core products RBD4059, RBD5044, and RBD1016, as well as to support pipeline assets in preclinical stages and enhance the technology platform [3]. Group 3: Investor Participation - Key cornerstone investors include Arc Avenue Asset Management, Bright Stone Holdings, and several asset management firms, collectively acquiring 42.5% of the offering [6][7]. - The cornerstone investors' total shareholding includes significant contributions from various funds and insurance companies, indicating strong institutional interest in Rebio [6]. Group 4: Financial Performance Projections - For the fiscal years ending December 31, 2023, and December 31, 2024, Rebio is projected to generate revenues of RMB 0.04 million and RMB 142.6 million, respectively, with net losses of RMB 437.3 million and RMB 281.5 million [8]. - The company anticipates a continued trend of net losses in the upcoming periods, with projected losses of RMB 141.6 million for the six months ending June 30, 2025 [8].

Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion through the issuance of 31.6104 million shares, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is a biopharmaceutical company focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, which targets FXI for the treatment of thrombotic diseases [1] - Rebio's pipeline includes seven self-developed drug assets currently in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases, with four of these in Phase 2 clinical trials [1] Clinical Development - In addition to the core product RBD4059, the company is advancing other clinical-stage products, including RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is also a differentiated siRNA candidate for coronary heart disease (CHD) [1] - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]

Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, aimed at treating thrombotic diseases, and has a pipeline of seven self-developed drug assets currently in clinical trials [1] Clinical Pipeline - The clinical pipeline includes treatments for cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1] - In addition to RBD4059, the company is advancing other clinical-stage products such as RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is a differentiated siRNA candidate for coronary heart disease (CHD) [1] Preclinical Projects - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]

Group 1 - Rebio Biopharma-B (6938.HK) has officially launched its IPO, planning to globally offer 27.4874 million H-shares at a price of HKD 57.97 per share, with the subscription period from December 31, 2025, to January 6, 2026, and expected trading to commence on January 9, 2026 [1][5][6] - The company, founded in 2007, focuses on the research and development of small nucleic acid drugs, particularly siRNA therapies, with a core product RBD4059 targeting FXI for thrombotic diseases [7][10][21] - Rebio has a robust pipeline with seven self-developed drug assets in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases [9][10] Group 2 - The global small nucleic acid drug market is projected to grow significantly, with a compound annual growth rate (CAGR) of 21.6% from 2019 to 2024, and 29.4% from 2024 to 2029 [14] - The company utilizes its proprietary RiboGalSTAR™ platform for liver-targeted drug development, which enhances delivery efficiency and specificity [15][20] - Rebio has received five IND/CTA approvals from regulatory authorities in 2024, including four for Phase II clinical trials, indicating strong progress in its clinical development [16] Group 3 - RBD4059 is the first siRNA drug in clinical stages for treating thrombotic diseases, showing significant efficacy in reducing FXI activity by up to 91.6% in clinical trials [26] - The drug's long-acting formulation allows for administration every 3-6 months, potentially improving patient compliance compared to traditional anticoagulants [28] - RBD5044, targeting high triglycerides, is the second siRNA drug in clinical development, demonstrating strong triglyceride-lowering effects and good safety profiles [30][34] Group 4 - The company has established a global R&D center in Sweden, Ribocure AB, which includes a clinical trial unit (CTU) for conducting independent clinical trials [40] - Rebio has formed strategic partnerships with major pharmaceutical companies, including Boehringer Ingelheim, to enhance its growth prospects and leverage its siRNA technology [41]

Group 1 - The core point of the article is that Rebio Biotech-B (6938.HK) is launching an IPO from today until January 6, 2026, with a share price of HKD 57.97 and plans to raise up to HKD 1.593 billion [1] - The offering consists of 27.4874 million shares, with approximately 10% allocated for public sale in Hong Kong and the remainder for international placement [1] - The expected listing date for the stock is January 9, 2026 [1] Group 2 - Approximately 37.4% of the net proceeds from the fundraising will be allocated to the research and development of the core product RBD4059 [1] - About 19.6% of the funds will be used for the development of RBD5044 [1] - Approximately 15.9% will be directed towards the research of RBD1016 [1] - Around 10.1% will finance pipeline assets that are in the preclinical trial application stage [1] - About 8.9% will be allocated to advance preclinical assets that have not yet entered the preclinical trial application stage and to enhance the technology platform [1] - Approximately 8.1% will be used for working capital and other general corporate purposes [1]